HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis
G. Nkontchou(Inserm), Michel Beaugrand(Hôpital Jean-Verdier), Imane Baghad, Véronique Grando–Lemaire, Dominique Roulot(Université Sorbonne Paris Nord), Y. Baazia(Assistance Publique – Hôpitaux de Paris), Nathalie Ganne‐Carrié(Inserm), Mounir Aout(Hôpital Lariboisière), Éric Vicaut(Université Paris Cité), Emmanuel Gordien(Université Paris Cité), Jean–Claude Trinchet(Hôpital Avicenne), Marianne Ziol(Assistance Publique – Hôpitaux de Paris), Abdelhalim Mahmoudi, M. Lhabadie
Cited by 178
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial
|The Lancet|2013|1.2k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
|Journal of Hepatology|2012|821
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
|New England Journal of Medicine|2018|605
Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke
|New England Journal of Medicine|2018|363